Research Analysts’ Weekly Ratings Changes for Gilead Sciences (GILD)

Gilead Sciences (NASDAQ: GILD) recently received a number of ratings updates from brokerages and research firms:

• 11/4/2026 – Gilead Sciences was given a new $196.00 price target by Jefferies Financial Group.
• 11/2/2026 – Gilead Sciences had its “outperform” rating reaffirmed by Sanford C. Bernstein. They now have a $175.00 price target on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by UBS Group from $175.00 to $195.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Gilead Sciences was given a new $175.00 price target by Needham & Company LLC.
• 10/30/2026 – Gilead Sciences had its price target raised by TD Cowen from $160.00 to $175.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Gilead Sciences had its “outperform” rating reaffirmed by BMO Capital Markets. They now have a $184.00 price target on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $170.00 to $190.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Citigroup from $165.00 to $188.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Scotiabank from $177.00 to $200.00. They now have a “sector outperform” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Morgan Stanley from $163.00 to $183.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Truist Financial from $158.00 to $181.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Wells Fargo & Company from $165.00 to $190.00. They now have an “overweight” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $126.00 to $131.00. They now have a “sector perform” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Needham & Company LLC from $170.00 to $200.00. They now have a “buy” rating on the stock.
• 10/30/2026 – Gilead Sciences had its price target raised by Cantor Fitzgerald from $155.00 to $175.00. They now have an “overweight” rating on the stock.
• 10/23/2026 – Gilead Sciences had its “buy” rating reaffirmed by Jefferies Financial Group. They now have a $185.00 price target on the stock.
• 10/20/2026 – Gilead Sciences had its price target raised by Bank of America from $168.00 to $172.00. They now have a “buy” rating on the stock.
• 10/12/2026 – Gilead Sciences had its “buy” rating reaffirmed by Bank of America. They now have a $164.00 price target on the stock.
• 10/8/2026 – Gilead Sciences had its price target raised by Royal Bank Of Canada from $123.00 to $126.00. They now have a “sector perform” rating on the stock.
• 10/8/2026 – Gilead Sciences had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $155.00 price target on the stock.
• 10/7/2026 – Gilead Sciences had its price target raised by Truist Financial from $150.00 to $158.00. They now have a “buy” rating on the stock.
• 10/7/2026 – Gilead Sciences had its price target raised by JPMorgan Chase & Co. from $160.00 to $170.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – Gilead Sciences had its price target lowered by Morgan Stanley from $165.00 to $163.00. They now have an “overweight” rating on the stock.
• 9/29/2026 – Gilead Sciences was downgraded by Zacks Research from “strong-buy” to “hold”.
• 9/19/2026 – Gilead Sciences was upgraded by Wall Street Zen from “hold” to “buy”.
• 9/14/2026 – Gilead Sciences was upgraded by Weiss Ratings from “hold (c-)” to “hold (c)”.
• 9/10/2026 – Gilead Sciences had its price target raised by HSBC from $155.00 to $175.00. They now have a “buy” rating on the stock.
• 9/5/2026 – Gilead Sciences was downgraded by Wall Street Zen from “buy” to “hold”.

Gilead Sciences Trading Up 4.2%

Shares of Gilead Sciences stock traded up $7.01 during mid-day trading on Wednesday, hitting $174.48. The stock had a trading volume of 9,634,568 shares, compared to its average volume of 6,839,528. The firm has a 50-day moving average of $151.77 and a two-hundred day moving average of $140.25. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $175.65. The company has a quick ratio of 0.95, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. The firm has a market cap of $216.41 billion, a P/E ratio of -55.22 and a beta of 0.35.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion for the quarter, compared to analyst estimates of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The business’s revenue for the quarter was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.47 EPS. Sell-side analysts forecast that Gilead Sciences, Inc. will post -1.03 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Shareholders of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio (DPR) is -103.80%.

Insider Buying and Selling at Gilead Sciences

In related news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Thursday, August 20th. The shares were sold at an average price of $145.02, for a total value of $725,100.00. Following the completion of the sale, the director owned 10,066 shares in the company, valued at approximately $1,459,771.32. This trade represents a 33.19% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $169.74, for a total value of $2,546,100.00. Following the completion of the sale, the chief executive officer directly owned 551,683 shares in the company, valued at approximately $93,642,672.42. The trade was a 2.65% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 126,881 shares of company stock valued at $19,252,455. 0.30% of the stock is currently owned by company insiders.

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19.

Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary.